This article was originally published in The Gray Sheet
Executive SummaryHelsinki, Finland-based company reaches a basic agreement with Swedish firm Gambro AB under which Instrumentarium will acquire Gambro's anaesthesia and intensive care business. The business being acquired is comprised of the Gambro Engstrom AB, Engstrom Elektromedizin GmbH, Soxil SpA, and Engstrom MIE Ltd. divisions, based in Sweden, Germany, Italy, and the U.K., respectively. The four businesses had combined 1993 sales of approximately $58 mil., according to Instrumentarium. Instrumentarium says the acquisition will "particularly strengthen" its Datex division in the areas of anaesthesia and critical care equipment, where there is "a strong trend towards integration of patient monitoring, anaesthesia delivery and information management." Datex posted 1993 sales of about $100 mil
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.